Last10K.com

Adams Respiratory Therapeutics, Inc. (1319439) SEC Filing 10-Q Quarterly report for the period ending Saturday, March 31, 2007

Adams Respiratory Therapeutics, Inc.

CIK: 1319439
 

Exhibit 99.1
(ADAMS RESPIRATORY LOGO)
     
 
  4 Mill Ridge Lane
 
  Mill Ridge Farm
 
  Chester, NJ 07930
 
  Main: 908-879-1400
 
  Fax: 908-879-9191
 
  www.adamsrt.com
ADAMS RESPIRATORY THERAPEUTICS REPORTS
FISCAL 2007 THIRD QUARTER FINANCIAL RESULTS
Solid year-over-year net sales growth driven by incremental sales of Delsym® and
Children’s Mucinex® and continued market penetration of Mucinex® DM
Highlights:
    Net sales of $84.0 million increased 11 percent.
 
    Retail consumption of Mucinex and Delsym products each increased more than 45 percent during the 2006-2007 cough/cold season in the cough/cold/allergy/sinus (C/C/A/S) category, according to Information Resources, Inc. (IRI) for the 28 weeks ended March 25, 2007.
 
    Adams’ dollar share of the total C/C/A/S category increased three market share points to 11.3 percent, for the 28 weeks ended March 25, 2007, versus prior year, according to IRI.
 
    Adams detailed the significant planned expansion and diversification of its product portfolio, including nine new OTC products, such as the Maximum Strength Mucinex and Mucinex Nasal Sprays product lines. (April)
 
    The New Drug Application, or NDA, for Mucinex with Codeine, a new prescription treatment for cough was accepted for filing by the FDA and is currently under regulatory review. (March)
 
    A settlement agreement was reached in the patent infringement lawsuit against Mutual Pharmaceutical. (March)
 
    An agreement was announced with MonoSol Rx, LLC that provides Adams access to oral thin-film drug delivery technology for future prescription and OTC products. (March)
CHESTER, N.J. (May 10, 2007) — Adams Respiratory Therapeutics, Inc. (NASDAQ: ARxT) today announced financial results for the fiscal third quarter ended March 31, 2007.
Commenting on the quarterly results, Michael J. Valentino, president and CEO said, “Overall, I am pleased with our solid top-line results and the in-season market performance of our brands. Our Mucinex and Delsym franchises both experienced the highest year-over-year sales growth of any brands in the cough/cold/allergy/sinus category, according to IRI for the 28 weeks ended March 25, 2007. We also exited the 2006-2007 cough/cold season with significant market share gains and increased consumer awareness. Additionally, we supported our key brands and newly launched products with effective consumer advertising and professional marketing support. All of these factors contributed to our exceptional performance in the competitive marketplace.”
Valentino added, “However, in spite of record retail consumption and strong market share gains for our brands this quarter, we believe our year-over-year growth in net sales was impacted primarily by

 


The following information was filed by Adams Respiratory Therapeutics, Inc. on Thursday, May 10, 2007 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Adams Respiratory Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adams Respiratory Therapeutics, Inc..

Continue

Assess how Adams Respiratory Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Adams Respiratory Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2007 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools
CIK: 1319439
Form Type: 10-Q Quarterly Report
Accession Number: 0000950144-07-004898
Submitted to the SEC: Tue May 15 2007 4:42:19 PM EST
Accepted by the SEC: Tue May 15 2007
Period: Saturday, March 31, 2007
Industry: Pharmaceutical Preparations

External Resources:

Bookmark the Permalink:
https://last10k.com/sec-filings/1319439/0000950144-07-004898.htm